AstraZeneca readies April EUA filing with 79% vaccine efficacy, first glimpse of elderly data and 100% protection against severe disease in US trial
Weeks into a chaotic vaccine rollout in Europe, AstraZeneca finally has the long-awaited Phase III data it needs to crack open the American market — without the safety scare. How big of a role it might play in the US, though, is less certain.
At the interim analysis, AZD1222 sported a 79% efficacy at preventing symptomatic Covid-19 — a figure squarely in between the 94% or 95% posted by its mRNA rivals and 72% claimed for J&J’s single-shot vaccine. The results were based on 141 symptomatic cases recorded across 32,449 volunteers, who were randomized 2:1 vaccine to placebo, although the breakdown wasn’t disclosed.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,800+ biopharma pros reading Endpoints daily — and it's free.